{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:13Z","timestamp":1792184653946,"version":"4.4.0"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Fasedienol (PH94B) is a pherine compound formulated as a nasal spray that is hypothesized to regulate olfactory\u2010amygdala circuits of fear and anxiety. Fasedienol's effect on the local electrogram of nasal chemosensory neurons (EGNR) and autonomic nervous system (ANS) responses versus steroidal hormones and controls in healthy adults is reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eight males and 8 females randomly received aerosolized control (propylene glycol) and study drugs (fasedienol, 17\u03b2\u2010estradiol, progesterone, cortisol, and testosterone, 0.4\u00a0\u03bcg each in propylene glycol) onto the nasal septum mucosal lining at 30\u2010min intervals over 2 sessions. EGNR was continuously monitored; autonomic parameters were recorded before and after administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fasedienol significantly increased EGNR amplitude (males: 5.0 vs. 0.6\u00a0mV, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001; females:5.7 vs. 0.6\u00a0mV, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001), and rapidly reduced respiratory rate (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.05), heart rate (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.01), and electrodermal activity (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.05) versus control. EGNR and ANS responses after steroidal hormone administration were similar to control. 81% reported feeling less tense\/more relaxed after receiving fasedienol, but not after receiving either control or steroidal hormones.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Intranasal fasedienol, but not control or steroidal hormones, activated EGNR and rapidly reduced ANS responses, consistent with sympatholytic effects. Combined with subjective reports, results suggest fasedienol may provide acute relief in anxiety conditions.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2892","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:53:30Z","timestamp":1704812010000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of fasedienol (PH94B) pherine nasal spray and steroidal hormones on electrogram responses and autonomic nervous system activity in healthy adult volunteers"],"prefix":"10.1002","volume":"39","author":[{"given":"Louis","family":"Monti","sequence":"first","affiliation":[{"name":"Vistagen Therapeutics, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Hanover","sequence":"additional","affiliation":[{"name":"Vistagen Therapeutics, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Salm\u00e1n","sequence":"additional","affiliation":[{"name":"Vistagen Therapeutics, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Baker","sequence":"additional","affiliation":[{"name":"Vistagen Therapeutics, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaakko","family":"Lappalainen","sequence":"additional","affiliation":[{"name":"Vistagen Therapeutics, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Smith","sequence":"additional","affiliation":[{"name":"Vistagen Therapeutics, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"3","key":"e_1_2_11_2_1","first-page":"302","article-title":"Effects of progestins on olfactory sensitivity and cognition","volume":"5","author":"Albertazzi P.","year":"2002","journal-title":"Climacteric"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041758"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1017\/s1461145712000119"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2014.03.011"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2004.11.001"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.595584"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159640"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212573"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1614701"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22546"},{"key":"e_1_2_11_12_1","volume-title":"Top\u2010line results from phase 3 PALISADE\u20102 trial of fasedienol (PH94B) nasal spray in social anxiety disorder [poster]","author":"Liebowitz M. R.","year":"2023"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.12101342"},{"key":"e_1_2_11_14_1","volume-title":"Brain and peripheral distribution of intranasal radiolabeled PH94B in laboratory rats [poster]","author":"Monti L.","year":"2022"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1017\/s109285292000190x"},{"key":"e_1_2_11_16_1","volume-title":"Social anxiety disorder","author":"National Institute of Mental Health","year":"2021"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2004.07.007"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0306\u20104530(02)00064\u20101"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.83"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001206.pub3"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2020.12.026"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T05:30:26Z","timestamp":1709789426000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/hup.2892"],"URL":"https:\/\/doi.org\/10.1002\/hup.2892","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"2023-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2892"}}